RE:RE:RE:RE:RE:RE:RE:Trog IV push dataOne needs to be cautious when talking about equivalent doses of TH1902 and docetaxel. By its nature, the PDC, even if it does not enter cells, will allow a higher MTD just because the release of free docetaxel in the bloodstream will be gradual over time, and the Cmax of docetaxel in the blood will be lower. That's why some efficacy signals would be hignly desirable out of phase Ia. Having only safety data will be disapointing and all the question marks will remain. You don't need to have an undeniable proof of concept, but at least good signs pointing towards that.
Wino115 wrote: Outstanding results given the endpoint for 1a is good safety tolerance (compare it to SOC or docetaxol alone at equivalent dose) and the support of a high dose for the extension trial. That would be outstanding since that's all that is planned. If the PK/PD can help understand more or if they've actually been able to scan and it's pointing in the right direction, that would be a bonus cake of outstanding.